• Whitehawk outlined a three-asset antibody-drug conjugate portfolio, including 2 clinical-stage programs and an IND expected mid-2026.
• Cash as of March 31, 2026 was USD 123 million, with runway expected into 2028 under current plans.
• Platform positioned around a DAR6 TOP1 inhibitor payload and cleavable linker, with preclinical benchmarks cited at 3-10x greater potency, 5-25x higher stability, and 2-3x higher safety margin versus an average TOP1 inhibitor ADC platform.
• Lead programs include HWK-007 targeting PTK7 and HWK-016 targeting MUC16, with first data readouts expected in 1H 2027.
• Third program HWK-206 targets SEZ6, with Phase 1 planned in small cell lung cancer and neuroendocrine neoplasms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.